PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting
Open accessAbstract
Poly(ADP-ribose) polymerases have shown true promise in early clinical studies due to reported activity in BRCA-associated cancers. PARP inhibitors may represent a potentially important new class of chemotherapeutic agents directed at targeting cancers with defective DNA-damage repair. In order to widen the prospective patient population that would benefit from PARP inhibitors, predictive biomarkers based on a clear understanding of the mechanism of action are required. In addition, a more sophisticated understanding of the toxicity profile is required if PARP inhibitors are to be employed in the curative, rather than the palliative, setting. PARP inhibitors have successfully moved into clinical practice in the past few years, with approval granted from the Food and Drug Administration (FDA) and European Medicines Agency (EMA) within the past two years. The United States FDA approval of olaparib applies to fourth-line treatment in germline BRCA-mutant ovarian cancer, and European EMA approval of olaparib for maintenance therapy in both germline and somatic BRCA-mutant platinum-sensitive ovarian cancer. This review covers the current understanding of PARP, its inhibition, and the basis of the excitement surrounding these new agents. It also evaluates future approaches and directions required to achieve full understanding of the intricate interplay of these agents at the cellular level.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
PARP inhibitors, notably olaparib, are significant therapeutic agents, particularly in cancers with defective DNA repair mechanisms, such as BRCA-mutated tumors.
“PARP inhibitors, notably olaparib, have emerged as significant therapeutic agents, particularly in cancers with defective DNA repair mechanisms, such as BRCA-mutated tumors [25].”
From Celastrol attenuates the invasion and migration and augments the anticancer effects of olaparib in prostate cancer (2024) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,854 · see citing works
SEER Cancer Statistics Review, 1975-2003
Ries, L. A. G., Harkins, D., Krapcho, M. F., Mariotto, A. B., Miller, B., Feuer, E. J., Clegg, L. X., Eisner, M. P., Horner, M., Howlader, N., et al. (2006) · Digital Archive @ GSU · Cited by 11,404 · see citing works
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018 · see citing works
The DNA damage response and cancer therapy
Lord, C. J., & Ashworth, A. (2012) · Nature · doi:10.1038/nature10760 · Cited by 1,843 · see citing works
Amé, J., Spenlehauer, C., & de MURCIA, G. (2004) · BioEssays · doi:10.1002/bies.20085 · Cited by 1,463 · see citing works
Effect of Screening on Ovarian Cancer Mortality
Buys, S. S. (2011) · JAMA · doi:10.1001/jama.2011.766 · Cited by 1,326 · see citing works
PARP inhibition: PARP1 and beyond
Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H., & Poirier, G. G. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2812 · Cited by 1,298 · see citing works
Alsop, K., Fereday, S., Meldrum, C. J., DeFazio, A., Emmanuel, C., George, J., Dobrovic, A., Birrer, M. J., Webb, P. M., Stewart, C. J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.8545 · Cited by 1,179 · see citing works
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086 · see citing works
Helleday, T. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.07.001 · Cited by 859 · see citing works
Frank, T. S. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.6.1480 · Cited by 813 · see citing works
Frank, T. S., Deffenbaugh, A. M., Reid, J., Hulick, M., Ward, B. E., Lingenfelter, B., Gumpper, K. L., Scholl, T., Tavtigian, S. V., Pruss, D., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.20.6.1480 · Cited by 557 · see citing works
Atchley, D. P. D., Albarracin, C., López, A., Valero, V., Amos, C., González-Angulo, A., Hortobagyi, G., & Arun, B. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6231 · Cited by 411 · see citing works
Arnaudeau, C., Lundin, C., & Helleday, T. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.4564 · Cited by 387 · see citing works
BRCA1 regulates p53-dependent gene expression
Ouchi, T., Monteiro, Á. N. A., August, A., Aaronson, S. A., & Hanafusa, H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.5.2302 · Cited by 375 · see citing works
Hennessy, B. T., Timms, K. M., Carey, M. S., Gutin, A., Meyer, L. A., Flake, D. D., Abkevich, V., Potter, J., Pruss, D., Glenn, P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.2997 · Cited by 372 · see citing works
Domchek, S. M., Aghajanian, C. A., Shapira‐Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M. L., Balmañà, J., Mitchell, G., Fried, G., Stemmer, S. M., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.12.020 · Cited by 295 · see citing works
Estrogen Receptor Status in BRCA1 - and BRCA2 -Related Breast Cancer
Foulkes, W. D., Metcalfe, K. A., Sun, P., Hanna, W. M., Lynch, H. T., Ghadirian, P., Tung, N., Olopade, O. I., Weber, B. L., McLennan, J., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-1061 · Cited by 293 · see citing works
PARP inhibitors in the management of breast cancer: current data and future prospects
Livraghi, L., & Garber, J. E. (2015) · BMC Medicine · doi:10.1186/s12916-015-0425-1 · Cited by 267 · see citing works
Global trends in breast cancer incidence and mortality
Porter, P. L. (2009) · Salud Pública de México · doi:10.1590/s0036-36342009000800003 · Cited by 222 · see citing works
Tutt, A. N. J., Lord, C. J., McCabe, N., Farmer, H., Turner, N. C., Martin, N. M. B., Jackson, S. P., Smith, G. C. M., & Ashworth, A. (2005) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2005.70.012 · Cited by 195 · see citing works
A Comprehensive Focus on Global Spectrum ofBRCA1andBRCA2Mutations in Breast Cancer
Karami, F., & Mehdipour, P. (2013) · BioMed Research International · doi:10.1155/2013/928562 · Cited by 173 · see citing works
Oplustilova, L., Wolanin, K., Mistrík, M., Kořínková, G., Šimková, D., Bouchal, J., Lenobel, R., Bártková, J., Lau, A., O’Connor, M. J., et al. (2012) · Cell Cycle · doi:10.4161/cc.22026 · Cited by 164 · see citing works
Condensin I Interacts with the PARP-1-XRCC1 Complex and Functions in DNA Single-Strand Break Repair
Heale, J. T., Ball, A. R., Schmiesing, J. A., Kim, J.-S., Kong, X., Zhou, S., Hudson, D. F., Earnshaw, W. C., & Yokomori, K. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.036 · Cited by 140 · see citing works
Poly(ADP-ribose) polymerase-1 (PARP-1) and its therapeutic implications
Sodhi, R. K., Singh, N., & Jaggi, A. S. (2010) · Vascular Pharmacology · doi:10.1016/j.vph.2010.06.003 · Cited by 131 · see citing works
Richter, S., Haroun, I., Graham, T., Eisen, A. F., Kiss, A., & Warner, E. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt312 · Cited by 112 · see citing works
Pejovic, T. B., & Nezhat, F. R. (2011) · Journal of Minimally Invasive Gynecology · doi:10.1016/j.jmig.2011.07.013 · Cited by 107 · see citing works
Resistance to PARP-Inhibitors in Cancer Therapy
Montoni, A., Robu, M., Pouliot, É., & Shah, G. M. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00018 · Cited by 102 · see citing works
Perspective on the Pipeline of Drugs Being Developed with Modulation of DNA Damage as a Target
Plummer, R. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0984 · Cited by 90 · see citing works
Role of BRCAgene dysfunction in breast and ovarian cancer predisposition
Scully, R. (2000) · Breast Cancer Research · doi:10.1186/bcr76 · Cited by 78 · see citing works
Review of Mammalian DNA Repair and Translational Implications
Hansen, W. K., & Kelley, M. R. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38861-5 · Cited by 77 · see citing works
Comen, E. A., & Robson, M. E. (2009) · Breast Diseases A Year Book Quarterly · doi:10.1016/s1043-321x(09)79253-7 · Cited by 61 · see citing works
Ghosh, S., Lu, Y., Katz, A. J., Hu, Y., & Li, R. (2006) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00242.2006 · Cited by 56 · see citing works
Poly(ADP-ribose) polymerase inhibition: a new direction for BRCAand triple-negative breast cancer?
Plummer, R. (2011) · Breast Cancer Research · doi:10.1186/bcr2877 · Cited by 54 · see citing works
Role of Biomarkers in the Development of PARP Inhibitors
Ganguly, B., Dolfi, S. C., Rodríguez-Rodríguez, L., Ganesan, S., & Hirshfield, K. M. (2016) · Biomarkers in Cancer · doi:10.4137/bic.s36679 · Cited by 39 · see citing works
Foulkes, W. D., Metcalfe, K., Sun, P., Hanna, W. M., Lynch, H. T., Ghadirian, P., Tung, N., Olopade, O. I., Weber, B. L., McLennan, J., et al. (2004) · TSpace (University of Toronto) · Cited by 19 · see citing works
Flagged first, then by citations
3 of the 39 references couldn’t be matched to a known paper.
Research works printed but not linked: 2
- [29]Livraghi L Garber JE PARP inhibitors in the management of breast cancer: current data and future prospects BMC Med 2015 13 188 26268938 PMC4535298
- [33]Oplustilova L Wolanin K Mistrik M Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment Cell Cycle 2012 11 3837 3850 22983061 PMC3495826
Cited by
Sorted by citations
Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening
Kim, M., Mun, H., Sung, C. O., Cho, E. J., Jeon, H.-J., Chun, S.-M., Jung, D. J., Shin, T. H., Jeong, G. S., Kim, D. K., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11867-6 · Cited by 812 · see citing works
BRCA Genes: The Role in Genome Stability, Cancer Stemness and Therapy Resistance
Gorodetska, I., Kozeretska, I. A., & Dubrovska, A. (2019) · Journal of Cancer · doi:10.7150/jca.30410 · Cited by 279 · see citing works
Francies, F. Z., Hull, R., Khanyile, R., & Dlamini, Z. (2020) · PubMed Central · Cited by 223 · see citing works
Current and Emerging Methods for Ovarian Cancer Screening and Diagnostics: A Comprehensive Review
Liberto, J. M., Chen, S.-Y., Shih, I., Wang, T., Wang, T., & Pisanic, T. R. (2022) · Cancers · doi:10.3390/cancers14122885 · Cited by 170 · see citing works
Alimbetov, D. S., Askarova, S., Umbayev, B. A., Davis, T., & Kipling, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061690 · Cited by 156 · see citing works
Targeting DNA damage repair in small cell lung cancer and the biomarker landscape
Sen, T., Gay, C. M., & Byers, L. A. (2018) · Translational Lung Cancer Research · doi:10.21037/tlcr.2018.02.03 · Cited by 137 · see citing works
Haynes, B. M., Murai, J., & Lee, J. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.09.003 · Cited by 137 · see citing works
Exploiting DNA repair defects in colorectal cancer
Reilly, N. M., Novara, L., Nicolantonio, F. D., & Bardelli, A. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12467 · Cited by 129 · see citing works
Recent advances in DDR (DNA damage response) inhibitors for cancer therapy
Cheng, B., Pan, W., Xing, Y., Xiao, Y., Chen, J., & Xu, Z. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114109 · Cited by 121 · see citing works
Glioblastoma: Current Status, Emerging Targets, and Recent Advances
Thakur, A., Faujdar, C., Sharma, R., Sharma, S., Malik, B., Nepali, K., & Liou, J. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01946 · Cited by 120 · see citing works
Wang, L., Yang, C., Xie, C., Jiang, J., Gao, M., Li, F., Li, Y., Bao, X., Fu, H., & Lou, L. (2019) · Cancer Science · doi:10.1111/cas.13947 · Cited by 106 · see citing works
Zinc finger domains as therapeutic targets for metal-based compounds – an update
Abbehausen, C. (2018) · Metallomics · doi:10.1039/c8mt00262b · Cited by 102 · see citing works
Harrision, D., Gravells, P., Thompson, R. H., & Bryant, H. E. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00191 · Cited by 101 · see citing works
Polyploidy formation in cancer cells: How a Trojan horse is born
Waś, H., Borkowska, A., Olszewska, A., Klemba, A., Marciniak, M., Synowiec, A., & Kiéda, C. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.003 · Cited by 98 · see citing works
Karam, S. D., Reddy, K., Blatchford, P. J., Waxweiler, T. V., DeLouize, A. M., Oweida, A. J., Somerset, H., Marshall, C. B., Young, C. D., Davies, K. D., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0467 · Cited by 95 · see citing works
DNA damaging agents and DNA repair: From carcinogenesis to cancer therapy
de Almeida, L. C., Calil, F. A., Machado‐Neto, J. A., & Costa-Lotufo, L. V. (2020) · Cancer Genetics · doi:10.1016/j.cancergen.2020.12.002 · Cited by 86 · see citing works
A review on epidermal growth factor receptor's role in breast and non-small cell lung cancer
Subramaniyan, V., Fuloria, S., Gupta, G., Kumar, D. H., Sekar, M., Sathasivam, K. V., Sudhakar, K., Alharbi, K. S., Almalki, W. H., Afzal, O., et al. (2021) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2021.109735 · Cited by 86 · see citing works
tRNA Deregulation and Its Consequences in Cancer
Santos, M., Varanda, A. S., Varanda, A. S., Oliveira, C. R. A. D., & Santos, M. A. S. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.05.011 · Cited by 85 · see citing works
Subcellular compartmentalization of NAD+ and its role in cancer: A sereNADe of metabolic melodies
Zhu, Y., Liu, J., Park, J., Rai, P., & Zhai, R. G. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.04.002 · Cited by 82 · see citing works
Almahli, H., Hadchity, É., Jaballah, M. Y., Daher, R., Ghabbour, H. A., Kabil, M. M., Al‐Shakliah, N. S., & Eldehna, W. M. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.01.034 · Cited by 78 · see citing works
Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in Glioblastoma
Ferri, A., Stagni, V., & Barilà, D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144910 · Cited by 76 · see citing works
Immunotherapy for breast cancer using EpCAM aptamer tumor-targeted gene knockdown
Zhang, Y., Xie, X., Yeganeh, P. N., Lee, D.-J., Valle‐García, D., Meza‐Sosa, K. F., Junqueira, C., Su, J., Luo, H. R., Hide, W., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2022830118 · Cited by 72 · see citing works
Germline Variants Impact Somatic Events during Tumorigenesis
Ramroop, J. R., Gerber, M. M., & Toland, A. E. (2019) · Trends in Genetics · doi:10.1016/j.tig.2019.04.005 · Cited by 68 · see citing works
Olaparib: A Novel Therapy for Metastatic Breast Cancer in Patients With a BRCA1/2 Mutation
Caulfield, S. E., Christine C. Davis, P., & Byers, K. (2019) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2019.10.2.6 · Cited by 65 · see citing works
Oxidative stress and aging: Learning from yeast lessons
Eleuthério, E. C. A., Brasil, A. D. A., França, M. B., de Almeida, D. S. G., Rona, G. B., & Magalhães, R. S. S. (2017) · Fungal Biology · doi:10.1016/j.funbio.2017.12.003 · Cited by 63 · see citing works
Janysek, D. C., Kim, J. S., Duijf, P. H. G., & Dray, E. V. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101012 · Cited by 62 · see citing works
Molecular pathways and therapeutic targets linked to triple-negative breast cancer (TNBC)
Mustafa, M., Abbas, K., Alam, M., Ahmad, W., Moinuddin, M., Usmani, N., Siddiqui, S. A., & Habib, S. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04772-6 · Cited by 57 · see citing works
Richard, I. A., Burgess, J. T., O'Byrne, K. J., & Bolderson, E. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.801200 · Cited by 58 · see citing works
Engineered extracellular vesicles for concurrent Anti-PDL1 immunotherapy and chemotherapy
Chen, Y., Wang, L., Zheng, M., Zhu, C., Wang, G., Xia, Y., Blumenthal, E. J., Mao, W., & Wan, Y. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.07.012 · Cited by 56 · see citing works
Lau, C.-H., Seow, K., & Chen, K.-H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158125 · Cited by 50 · see citing works
Mintz, R. L., Lao, Y., Chi, C., He, S., Li, M., Quek, C. H., Shao, D., Chen, B., Han, J., Wang, S., et al. (2019) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10152 · Cited by 50 · see citing works
Triple negative breast cancer: new therapeutic approaches and BRCA status
Eskiler, G. G., Çeçener, G., Egelí, Ü., & Tunca, B. (2018) · Apmis · doi:10.1111/apm.12836 · Cited by 49 · see citing works
Emerging therapeutic agents for genitourinary cancers
Zarrabi, K. K., Paroya, A., & Wu, S. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0780-z · Cited by 48 · see citing works
PD-1/PD-L1 and DNA Damage Response in Cancer
Kciuk, M., Kołat, D., Kałuzińska‐Kołat, Ż., Gawrysiak, M., Drozda, R., Çeli̇k, İ., & Kontek, R. (2023) · Cells · doi:10.3390/cells12040530 · Cited by 44 · see citing works
The Role of Tumor Biomarkers in Tailoring the Approach to Advanced Ovarian Cancer
Tonti, N., D’Augè, T. G., Cuccu, I., Angelis, E. D., D’Oria, O., Perniola, G., Laganà, A. S., Etrusco, A., Ferrari, F. G., Saponara, S., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011239 · Cited by 44 · see citing works
Inhibiting the MCM8‐9 complex selectively sensitizes cancer cells to cisplatin and olaparib
Morii, I., Iwabuchi, Y., Mori, S., Suekuni, M., Natsume, T., Yoshida, K., Sugimoto, N., Kanemaki, M. T., & Fujita, M. (2019) · Cancer Science · doi:10.1111/cas.13941 · Cited by 44 · see citing works
Roles for MDC1 in cancer development and treatment
Ruff, S., Logan, S. K., Garabedian, M. J., & Huang, T. T. (2020) · DNA repair · doi:10.1016/j.dnarep.2020.102948 · Cited by 42 · see citing works
PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data
Moutafi, M. K., Economopoulou, P., Rimm, D. L., & Psyrri, A. K. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2021.105292 · Cited by 44 · see citing works
Advancing cancer therapy: new frontiers in targeting DNA damage response
Qian, J., Liao, G., Chen, M., Peng, R., Yan, X., Du, J., Huang, R., Pan, M., Lin, Y., Gong, X., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1474337 · Cited by 39 · see citing works
Wu, X., Zhu, J., Wang, J., Lin, Z., Yin, R., Sun, W., Zhou, Q., Zhang, S., Wang, D., Shi, H., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1186 · Cited by 39 · see citing works
Zakrzewski, F., Gieldon, L., Rump, A., Seifert, M., Grützmann, K., Krüger, A., Loos, S., Zeugner, S., Hackmann, K., Porrmann, J., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5584-6 · Cited by 36 · see citing works
Therapeutic Options for Metastatic Breast Cancer
Sambi, M., Qorri, B., Harless, W. W., & Szewczuk, M. R. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-20301-6_8 · Cited by 37 · see citing works
Chadha, K., Chheda, P., Pande, S. S., Dama, T., Vinarkar, S., Chanekar, M., Limaye, S., & Shah, N. (2020) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_101_19 · Cited by 35 · see citing works
Loizzi, V., Ranieri, G., Laforgia, M., Gadaleta, C. D., Gargano, G., Kardhashi, A., Liso, M. D., Naglieri, E., Vecchio, V. D., Cicinelli, E., et al. (2020) · Oncology Letters · doi:10.3892/ol.2020.11951 · Cited by 34 · see citing works
Shaik, B., Zafar, T., Balasubramanian, K., & Gupta, S. P. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620999201111155426 · Cited by 34 · see citing works
Putri, J. F., Bhargava, P., Dhanjal, J. K., Yaguchi, T., Sundar, D., Kaul, S. C., & Wadhwa, R. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1500-9 · Cited by 33 · see citing works
Advancements in the Treatment of Triple-Negative Breast Cancer: A Narrative Review of the Literature
Landry, I., Sumbly, V., & Vest, M. (2022) · Cureus · doi:10.7759/cureus.21970 · Cited by 31 · see citing works
The Implication of Topoisomerase II Inhibitors in Synthetic Lethality for Cancer Therapy
Matias-Barrios, V. M., & Dong, X. (2023) · Pharmaceuticals · doi:10.3390/ph16010094 · Cited by 31 · see citing works
Hernandez, A. L., Young, C. D., Bian, L., Weigel, K. J., Nolan, K., Frederick, B. A., Han, G., He, G., Trahan, G. D., Rudolph, M. C., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0514 · Cited by 31 · see citing works
Kumar, M., Jaiswal, R. K., Prasad, R. R., Yadav, S. S., Kumar, A., Yadava, P. K., & Singh, R. P. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118994 · Cited by 31 · see citing works
ATF6-Mediated Signaling Contributes to PARP Inhibitor Resistance in Ovarian Cancer
McMellen, A. N., Yamamoto, T. M., Qamar, L., Sanders, B. E., Nguyen, L. L., Chavez, D. R. O., Bapat, J., Berning, A. A., Post, M. D., Johnson, J., et al. (2022) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-22-0102 · Cited by 30 · see citing works
Parp Inhibitors: A Tsunami of Indications in Different Malignancies
Haddad, G., Saadé, M. C., Eid, R., Haddad, F., & Kourié, H. R. (2020) · Pharmacogenomics · doi:10.2217/pgs-2019-0113 · Cited by 29 · see citing works
Das, P. K., Matada, G. S. P., Pal, R., Maji, L., Dhiwar, P. S., Manjushree, B. V., & Viji, M. P. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116535 · Cited by 29 · see citing works
Novel Therapeutic Strategies for CDK4/6 Inhibitors in Metastatic Castrate-Resistant Prostate Cancer
Kase, A. M., Copland, J. A., & Tan, W. W. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s266085 · Cited by 28 · see citing works
Moustafa, D., Elwahed, M. R. A., Elsaid, H. H., & Parvin, J. D. (2021) · PLoS ONE · doi:10.1371/journal.pone.0235025 · Cited by 28 · see citing works
Excessive transcription-replication conflicts are a vulnerability of BRCA1 -mutant cancers
Patel, P. S., Algouneh, A., Krishnan, R., Reynolds, J. J., Nixon, K. C. J., Hao, J., Lee, J., Feng, Y., Fozil, C., Stanić, M., et al. (2023) · Nucleic Acids Research · doi:10.1093/nar/gkad172 · Cited by 26 · see citing works
Advances in PARP Inhibitors for Prostate Cancer
Tisseverasinghe, S., Bahoric, B., Anidjar, M., Probst, S., & Niazi, T. M. (2023) · Cancers · doi:10.3390/cancers15061849 · Cited by 26 · see citing works
Targeting NAD+ Metabolism to Enhance Radiation Therapy Responses
Lewis, J. E., Singh, N., Holmila, R. J., Sumer, B. D., Williams, N. S., Furdui, C. M., Kemp, M. L., & Boothman, D. A. (2018) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2018.10.009 · Cited by 26 · see citing works
Universal Approach to De Novo Drug Design for Target Proteins Using Deep Reinforcement Learning
Zhang, Y., Li, S., Xing, M., Yuan, Q., He, H., & Sun, S. (2023) · ACS Omega · doi:10.1021/acsomega.2c06653 · Cited by 26 · see citing works
Siraj, A. K., Pratheeshkumar, P., Parvathareddy, S. K., Divya, S. P., Al‐Dayel, F., Tulbah, A. M., Ajarim, D. S., & Al-Kuraya, K. S. (2018) · Oncotarget · doi:10.18632/oncotarget.26470 · Cited by 25 · see citing works
Breast cancer and its therapeutic targets: A comprehensive review
Singh, A., Mishra, R., & Mazumder, A. (2023) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14384 · Cited by 25 · see citing works
Hussain, S. A. (2020) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_2_20 · Cited by 24 · see citing works
Calheiros, J., Corbo, V., & Saraiva, L. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188914 · Cited by 26 · see citing works
How Macrophages Become Transcriptionally Dysregulated: A Hidden Impact of Antitumor Therapy
Medvedeva, G. F., Kuzmina, D. O., Nuzhina, J., Shtil, A. A., & Сергеевна, Д. М. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052662 · Cited by 23 · see citing works
Huang, X., Li, X., Shan, W., Chen, Y., Zhu, Q., & Xia, B.-R. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1131342 · Cited by 23 · see citing works
An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective
Cordani, N., Bianchi, T., Ammoni, L. C., Cortinovis, D. L., Cazzaniga, M. E., Lissoni, A. A., Landoni, F., & Canova, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241511890 · Cited by 23 · see citing works
Xie, T., Dickson, K.-A., Yee, C., Ma, Y., Ford, C. E., Bowden, N. A., & Marsh, D. J. (2022) · Cancers · doi:10.3390/cancers14194621 · Cited by 23 · see citing works
A review on mechanisms of resistance to PARP inhibitors
Desai, C. J., Pathak, A. B., Limaye, S. A., Maniar, V., & Joshi, A. (2022) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_53_21 · Cited by 22 · see citing works
Stone, N. E., Jaramillo, S. A., Jones, A. N., Vazquez, A. J., Martz, M., Versluis, L. M., Raniere, M. O., Nunnally, H. E., Zarn, K. E., Nottingham, R. D., et al. (2021) · mBio · doi:10.1128/mbio.03495-20 · Cited by 22 · see citing works
Xu, B., Yin, Y., Dong, M., Song, Y., Li, W., Huang, X., Wang, T., He, J., Mu, X., Li, L., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3575 · Cited by 21 · see citing works
Jang, A., Sartor, O. A., Barata, P. C., & Paller, C. J. (2020) · Cancers · doi:10.3390/cancers12113467 · Cited by 20 · see citing works
Friedlander, M. L., Mileshkin, L., Lombard, J. M., Frentzas, S., Gao, B., Wilson, M. K., Meniawy, T. M., Baron-Hay, S. E., Briscoe, K. P., McCarthy, N. J., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02349-0 · Cited by 18 · see citing works
Topical Transdermal Chemoprevention of Breast Cancer: Where Will Nanomedical Approaches Deliver Us?
Mojeiko, G., Passos, J. S., Apolinário, A. C., & Lopes, L. B. (2021) · Nanomedicine · doi:10.2217/nnm-2021-0130 · Cited by 18 · see citing works
Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology
Shah, S. M., Demidova, E. V., Lesh, R. W., Hall, M. J., Daly, M. B., Meyer, J. E., Edelman, M. J., & Arora, S. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102337 · Cited by 16 · see citing works
Ciardiello, F., Bang, Y., Cervantes, A. M. R., Dvorkin, M. V., Lopez, C. D., Metges, J., Ruiz, A. S., Calvo, M., Strickland, A. H., Kannourakis, G., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.5997 · Cited by 16 · see citing works
Choi, P. J., Cooper, E. A., Schweder, P. M., Mee, E. T., Turner, C. P., Faull, R. L. M., Denny, W. A., Dragunow, M., Park, T., & Jose, J. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127252 · Cited by 17 · see citing works
Feldmann, J., Li, Y., & Tor, Y. (2019) · Chemistry - A European Journal · doi:10.1002/chem.201805520 · Cited by 16 · see citing works
Recent advances in cancer therapy using PARP inhibitors
Kaur, S. D., Chellappan, D. K., Aljabali, A. A. A., Tambuwala, M. M., Dua, K., & Kapoor, D. N. (2022) · Medical Oncology · doi:10.1007/s12032-022-01840-7 · Cited by 16 · see citing works
Lev, A., Deihimi, S., Shagisultanova, E. I., Xiu, J., Lulla, A. R., Dicker, D. T., & El‐Deiry, W. S. (2017) · Cancer Biology & Therapy · doi:10.1080/15384047.2017.1364323 · Cited by 16 · see citing works
The Role of Niraparib for the Treatment of Ovarian Cancer
Ethier, J.-L., Lheureux, S., & Oza, A. M. (2018) · Future Oncology · doi:10.2217/fon-2018-0101 · Cited by 16 · see citing works
Ovarian Cancer: Molecular Classification and Targeted Therapy
Ravindran, F., & Choudhary, B. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.95967 · Cited by 16 · see citing works
The Role of the AT-Rich Interaction Domain 1A Gene (ARID1A) in Human Carcinogenesis
Li, J. J., & Lee, C. S. (2023) · Genes · doi:10.3390/genes15010005 · Cited by 15 · see citing works
Alradwan, I., Zhi, P., Zhang, T., Lip, H., Zetrini, A. E., He, C.-S., Henderson, J. T., Rauth, A. M., & Wu, X.-Y. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.11.061 · Cited by 15 · see citing works
[PARP Inhibitors: From the Mechanism of Action to Clinical Practice].
Branco, C., & Paredes, J. (2022) · PubMed · doi:10.20344/amp.13870 · Cited by 15 · see citing works
Mampunye, L., van der Merwe, N. C., Grant, K. A., Peeters, A. V., Torrorey-Sawe, R., French, D. J., Moremi, K. E., Kidd, M., van Eeden, P. C., Pienaar, F. M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.619817 · Cited by 14 · see citing works
Wang, Q., López‐Ozuna, V. M., Baloch, T., Bithras, J., Amin, O., Kessous, R., Kogan, L., Laskov, I., & Yasmeen, A. (2019) · Cancer Medicine · doi:10.1002/cam4.2738 · Cited by 14 · see citing works
Huang, C., Tsai, Y., Liu, C., Lien, P., Lin, Y., Chao, T., Feng, C.-J., Chen, Y.-J., Lai, J., Phan, N. N., et al. (2022) · Annals of Surgical Oncology · doi:10.1245/s10434-022-11347-0 · Cited by 14 · see citing works
Role of PARP1 regulation in radiation-induced rescue effect
Pathikonda, S., Cheng, S. H., & Yu, K. N. (2020) · Journal of Radiation Research · doi:10.1093/jrr/rraa023 · Cited by 14 · see citing works
Kerliu, L., Myruski, S., Bhatti, A., Soni, P., Petrosius, P., Pervanas, H. C., & Horton, E. R. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020912749 · Cited by 13 · see citing works
BRCA mutations in pancreatic cancer and progress in their targeting
Alkassis, S., Yazdanpanah, O., & Philip, P. A. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.1957462 · Cited by 12 · see citing works
Uličná, L., Kimmey, S. C., Weber, C. M., Allard, G. M., Wang, A., Bui, N. Q., Bendall, S. C., Crabtree, G. R., Bean, G. R., & Rechem, C. V. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-1360 · Cited by 12 · see citing works
Sequential therapeutic targeting of ovarian Cancer harboring dysfunctional BRCA1
Baloch, T., López‐Ozuna, V. M., Wang, Q., Matanis, E., Kessous, R., Kogan, L., Yasmeen, A., & Gotlieb, W. H. (2019) · BMC Cancer · doi:10.1186/s12885-018-5250-4 · Cited by 12 · see citing works
Dickson, K.-A., Xie, T., Evenhuis, C., Ma, Y., & Marsh, D. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22168506 · Cited by 11 · see citing works
Public Awareness and Acceptability of PGT-M in Cancer Predisposition Syndromes
Calosci, D., Passaglia, L., Gabbiato, I., Cartisano, F., Affuso, R., Sorrentino, U., & Zuccarello, D. (2023) · Genes · doi:10.3390/genes14112069 · Cited by 11 · see citing works
Targeting of RecQ Helicases as a Novel Therapeutic Strategy for Ovarian Cancer
Maity, J., Horibata, S., Zurcher, G., & Lee, J.-M. (2022) · Cancers · doi:10.3390/cancers14051219 · Cited by 11 · see citing works
Wang, J., & Zhu, J. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-2252 · Cited by 11 · see citing works
Zeng, X., Jiang, S., Ruan, S., Guo, Z., Guo, J., Liu, M., Ye, C., & Dong, J. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12187 · Cited by 11 · see citing works
Through the Looking Glass: Updated Insights on Ovarian Cancer Diagnostics
Chakraborty, S., Shenoy, P. S., Mehrotra, M., Phadte, P., Singh, P., Rekhi, B., & Ray, P. (2023) · Diagnostics · doi:10.3390/diagnostics13040713 · Cited by 10 · see citing works
Matanes, E., López‐Ozuna, V. M., Octeau, D., Baloch, T., Racovitan, F., Dhillon, A. K., Kessous, R., Raban, O., Kogan, L., Salvador, S. C., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.745981 · Cited by 10 · see citing works
Treatment Outcomes in Male Breast Cancer: A Retrospective Analysis of 161 Patients
Wan, B. A., Ganesh, V., Zhang, L., Sousa, P., Drost, L., Lorentz, J., Vesprini, D., Lee, J., Rakovitch, E., Lu, F., et al. (2018) · Clinical Oncology · doi:10.1016/j.clon.2018.02.026 · Cited by 10 · see citing works
- Authors
- Dziadkowiec, K. N., Gąsiorowska, E., Nowak-Markwitz, E., & Jankowska, A.
- Affiliations
- Poznan University of Medical Sciences (PL)
- Corresponding author
- Dziadkowiec, Karolina N.
- Venue
- Menopausal Review
- Publisher
- Termedia Sp. z.o.o.
- Published
- 2016
- Volume
- 4
- Issue
- 4
- Pages
- 215-219
- ISSN
- 1643-8876 (ISSN-L)
- PMC
- PMC5327624
- OpenAlex
- W2588625168
- Cited by
- 191
- References
- 39
- Citations by year
- 2026: 3 · 2025: 15 · 2024: 20 · 2023: 27 · 2022: 28 · 2021: 28 · 2020: 25 · 2019: 20 · 2018: 21 · 2017: 4
- FWCI
- 1.51
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc-sa
- Locations
- Menopause Review/Przegląd Menopauzalny (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Keywords
- PARP inhibitors, poly(ADP-ribose) polymerase, BRCA1 mutation, BRCA2 mutation, DNA repair deficiency, olaparib, predictive biomarkers, platinum-sensitive ovarian cancer, maintenance therapy, mechanism of action
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
